Evidence map›Paper›PMID 16829611›Full record

ArticleClinical and vaccine immunology : CVI2006

Different levels of immunogenicity of two strains of Fowlpox virus as recombinant vaccine vectors eliciting T-cell responses in heterologous prime-boost vaccination strategies.

Matthew G Cottingham, Andre van Maurik, Manola Zago, Angela T Newton, Richard J Anderson, M Keith Howard, Jörg Schneider, Michael A Skinner

Abstract readComparative Study
In one paragraph

Article in Clinical and vaccine immunology : CVI, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Flow Cytometric Evaluation of CD4Archives of Razi Institute · 2021
    Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Matthew G CottinghamDepartment of Virology, Division of Investigative Science, Faculty of Medicine, Imperial College, St. Mary's Campus, Norfolk Place, London W2 1PG, United Kingdom.
Andre van Maurik
Manola Zago
Angela T Newton
Richard J Anderson
M Keith Howard
Jörg Schneider
Michael A Skinner

Funding

Biotechnology and Biological Sciences Research Council BBS/B/00115/2
6 · The paper itself

Abstract

The FP9 strain of F has been described as a more immunogenic recombinant vaccine vector than the Webster FPV-M (FPW) strain (R. J. Anderson et al., J. Immunol. 172:3094-3100, 2004). This study expands the comparison to include two separate recombinant antigens and multiple, rather than single, independent viral clones derived from the two strains. Dual-poxvirus heterologous prime-boost vaccination regimens using individual clones of recombinant FP9 or FPW in combination with recombinant modified V Ankara expressing the same antigen were evaluated for their ability to elicit T-cell responses against recombinant antigens from Plasmodium berghei (circumsporozoite protein) or human immunodeficiency virus type 1 (a Gag-Pol-Nef fusion protein). Gamma interferon enzyme-linked immunospot assay and fluorescence-activated cell sorting assays of the responses to specific epitopes confirmed the approximately twofold-greater cellular immunogenicity of FP9 compared to FPW, when given as the priming or boosting immunization. Equality of transgene expression in mouse cells infected with the two strains in vitro was verified by Western blotting. Directed partial sequence analysis and PCR analysis of FPW and comparison to available whole-genome sequences revealed that many loci that are mutated in the highly attenuated and culture-adapted FP9 strain are wild type in FPW, including the seven multikilobase deletions. These "passage-specific" alterations are hypothesized to be involved in determining the immunogenicity of fowlpox virus as a recombinant vaccine vector.

Indexed as

AIDS VaccinesAnimalsFemaleFowlpox virusFusion Proteins, gag-polGene Products, nefGenetic VectorsHIV-1HumansImmunization, SecondaryInterferon-gammaMalaria VaccinesMiceMice, Inbred BALB Cnef Gene Products, Human Immunodeficiency VirusPlasmodium bergheiAIDS VaccinesFusion Proteins, gag-polGene Products, nefInterferon-gammaMalaria Vaccinesnef Gene Products, Human Immunodeficiency VirusPolyproteinsProtozoan ProteinsVaccines, DNA

Identifiers

PMID16829611
PMCPMC1489571

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.